Is LeMaitre Vascular, Inc. overvalued or undervalued?

As of 27 February 2025, LeMaitre Vascular, Inc. has moved from an expensive to a fair valuation grade. The company is currently fairly valued based on its financial metrics. The P/E ratio stands at 45, while the industry average is notably lower, indicating a premium valuation. Additionally, the EV to EBITDA ratio is 30.21, and the PEG ratio is 1.43, suggesting that while the company is priced higher than some peers, it may still offer growth potential.
In comparison to its peers, LeMaitre Vascular's P/E ratio of 43.25 is significantly higher than Tandem Diabetes Care, which is at -12.30, and STAAR Surgical Co. at -11.59, both of which are considered risky investments. Despite its fair valuation, LeMaitre's recent stock performance has been mixed, with a year-to-date return of -9.51% compared to the S&P 500's 2.44%, although it has outperformed the index over a three-year period with a return of 86.12%.